Dalmane (flurazepam hydrochloride) is a prescription sedative-hypnotic agent generally used for the short-term management of symptomatic insomnia in adults. It is relevant in clinical settings that involve acute or unstable symptom patterns.

The medication is commonly used across conditions presenting with acute episodes and recurrent, episodic manifestations of poor sleep. It is applied in addressing symptom clusters that may interfere with daily comfort, specifically: difficulty initiating sleep, frequent nocturnal awakenings, and early morning awakening.

Relief of Sleep Difficulty Symptoms

This domain addresses symptoms of increased neurological or muscular activity that prevent the easy transition to sleep. The key benefit is that it may assist with a faster onset of sleep, which provides supportive relief during periods of increased discomfort or tension and contributes to improved day-to-day comfort. For those struggling to maintain rest, Dalmane supports sustained rest, assisting with maintaining functional stability.

Support for Acute Sleep Deficiency

The medication is applied during phases of increased distress or discomfort, such as insomnia triggered by a temporary stressful life event. It is relevant for managing symptoms that interfere with daily comfort, and may assist patients with coping more steadily with difficult sleep episodes, supporting the maintenance of functional stability during these phases.

Supportive Focus: Insomnia Symptoms
Therapeutic Scope: Symptomatic management of sleep onset and sleep maintenance disturbances.
Key Benefits: Supports sustained rest and assists with a faster onset of sleep.

Regulatory References

1. DailyMed official label information provided by the NIH

Dalmane (flurazepam) eligibility is strictly defined by regulatory documents based on contraindications, age, and existing health conditions.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated and must not be used by individuals with:

• Known hypersensitivity or severe allergic reaction (e.g., angioedema) to flurazepam or other benzodiazepines.
• Pregnancy (categorized as X by the FDA).
• Severe hepatic insufficiency (severe liver failure).
• Myasthenia gravis (neuromuscular disease).
• Severe respiratory impairment or significant sleep apnea syndrome.

Age and Condition-Specific Restrictions

Population	Official Eligibility Status
Children (< 15 years)	Not recommended; safety and effectiveness have not been established in this age group. Some labels state use is contraindicated.
Older Adults (ge 65 years)	Conditional Use; the starting dose must be limited (typically to 15 mg) due to increased sensitivity and risk of adverse effects like confusion and falls.
Pregnant Women	Contraindicated (Category X); the patient should be instructed to discontinue the drug prior to becoming pregnant.
Breastfeeding Women	Not recommended; use should be avoided as the drug may accumulate and cause adverse effects in the infant.
Hepatic or Renal Impairment	Conditional Use; for non-severe impairment, dose reduction (e.g., to 15 mg) is required due to slower clearance. Severe hepatic insufficiency is a contraindication.

These constraints ensure that the drug is used only in populations where the regulatory authorities have assessed an acceptable risk profile, excluding those with absolute prohibitions or requiring use only under strict limits.

Dalmane Interactions with other Medicines and Products

The interaction profile of Dalmane (flurazepam hydrochloride) is officially documented by regulatory agencies, focusing primarily on additive central nervous system (CNS) effects and altered drug clearance.

Formally Documented Interaction Patterns

Interaction Pattern	Interacting Substance Categories/Examples	Official Regulatory Description
Pharmacodynamic Reinforcement	Alcohol, Opioids, other CNS Depressants (e.g., Antipsychotics, Sedative Antihistamines)	Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death; additive effects are cautioned with alcohol and other CNS depressants.
Exposure-Altering (Reduced Clearance)	Hepatic Enzyme Inhibitors (e.g., Cimetidine, Erythromycin)	Compounds that inhibit hepatic enzymes may enhance the activity and exposure of benzodiazepines, increasing potential effects.
Exposure-Altering (Increased Clearance)	Hepatic Enzyme Inducers (e.g., Rifampin), Heavy Smoking	Substances that accelerate flurazepam metabolism may reduce the drug's intended effect.

Interaction-Related Restrictions and Constraints

• Contraindicated Combinations: The consumption of alcohol is explicitly forbidden during treatment, and co-administration with opioids carries the highest level of warning due to the risk of severe CNS depression.
• Population-Specific Cautions: Dosage must be adjusted and limited in elderly or debilitated patients to mitigate the increased risk of oversedation and ataxia resulting from reduced drug clearance.
• Timing Constraint: The medication should not be taken when a full night's rest (7 to 8 hours) cannot be ensured before resuming active function.

Dalmane (flurazepam) is a central nervous system (CNS) depressant whose action is mediated by the gamma-aminobutyric acid type A (GABAA) receptor complex. This receptor is the primary mediator of inhibitory neurotransmission in the brain. Flurazepam and its chief active metabolite, N-desalkylflurazepam, operate as positive allosteric modulators of the GABAA receptor, meaning they do not activate the receptor directly.

Binding occurs at an allosteric site located between the alpha and gamma subunits of the pentameric GABAA receptor. This interaction induces a conformational change that increases the receptor’s affinity for the endogenous inhibitory neurotransmitter, GABA. The enhanced binding of GABA results in a greater frequency of chloride ion (Cl^-) channel opening.

The subsequent influx of negatively charged Cl^- ions into the postsynaptic neuron causes hyperpolarization of the neuronal membrane. This decreased membrane potential makes the neuron less responsive to excitatory stimuli, thus reducing the probability of action potential generation and decreasing the rate of signal transmission across the affected neural pathways. The system-level physiological consequence is a generalized reduction in CNS neuronal excitability across key brain regions.

Official Administration Guidelines for Flurazepam Hydrochloride

The use of flurazepam hydrochloride (Dalmane) is governed by specific instructions regarding its administration route, dosage, frequency, and duration. The medication is supplied as 15 mg and 30 mg oral capsules for administration by mouth.

Dosing and Scheduling

The usual starting dose for adults is 30 mg taken once daily, although a lower dose of 15 mg may be sufficient for some individuals. The capsule must be swallowed whole with water, without chewing. A crucial instruction is the timing: the daily dose must be taken immediately at bedtime (when the patient is ready to fall asleep), and not sooner. The medication is not intended for dosing earlier in the evening.

Use Patterns and Duration

Flurazepam is restricted to short-term use. Treatment should be limited to the shortest duration necessary, generally not exceeding four weeks, with this period including any necessary gradual dose reduction. This restriction is in place because the drug has been determined to be effective for at least 28 consecutive nights. To stop the medicine after continuous use, a gradual tapering of the dosage is required, and patients are explicitly instructed not to take a double dose to compensate for a missed one.

Population-Specific Adjustments

Dosing must be modified for certain populations. The initial dose for older or debilitated patients, as well as those with hepatic or renal impairment, should not exceed 15 mg once daily. The use of flurazepam hydrochloride is not recommended for adolescents under the age of 15.

Research Evidence / Overview of Studies for Dalmane (Flurazepam)

---

Evidence for Use in Symptomatic Insomnia

Research exploring flurazepam's use for symptomatic insomnia—which includes difficulty falling asleep and staying asleep—has relied on short-term Randomized Controlled Trials (RCTs) and specialized sleep laboratory studies. These studies were conducted during periods of increased symptom activity and applied in research contexts involving fluctuating symptom patterns. These trials primarily focused on monitoring changes in sleep parameters during short-term administration. Studies explored both acute (single-night) and subacute (up to a few weeks) measurements in sleep characteristics.

Sleep laboratory studies, which involve objective monitoring called polysomnography, reported how symptoms evolved in the observed populations. Researchers monitored and recorded changes in the time it took subjects to fall asleep (sleep latency) and the total time subjects remained asleep. Some trials described patterns in measurements of sleep maintenance, including monitoring the amount of time subjects were awake after first falling asleep. In general, research documents the measurements recorded during the study period, primarily during the initial one to four weeks of use.

---

Objective and Subjective Outcomes Examined

The clinical evidence landscape for flurazepam involves two main types of measurements. Objective outcomes were monitored using polysomnography, which provided data related to sleep characteristics and physiological strain. This research examined outcomes related to total sleep time, the amount of time spent in the deepest sleep stages, and the frequency of awakenings. Subjective outcomes focused on patient-reported outcomes describing perceived discomfort. Applied in studies examining patient-reported experiences, these measurements included how patients estimated the time it took them to fall asleep and their overall assessment of sleep quality. Findings help contextualize how patients reported their experience during the defined study intervals.

---

Evidence in Special Populations

Research has explored the effects of flurazepam in specific patient groups, notably geriatric patients (older adults, 65+ years). Flurazepam was evaluated in this population to study outcomes related to functional imbalance and activity level. Studies monitored the responses over defined time intervals, and findings described patterns observed in these particular groups. Limited information is available for certain groups, which restricts broad findings relative to the evidence base for younger adults. Studies also specifically included and recorded measurements in geriatric patients, examining patterns in this population relative to those observed in younger adults.

---

Long-term Follow-up and Duration of Study

The body of research on flurazepam primarily involves studies conducted during periods of acute or short-term sleep disturbance. Short-term RCTs typically monitor responses over periods of 7 to 14 consecutive nights. Specialized sleep laboratory research extended follow-up durations to observe responses for up to 28 consecutive nights of administration. This research provides insight into short-term changes in sleep parameters. Studies have also monitored sleep patterns during the first one or two nights after the medication was stopped, describing measurements attributed to the continued presence of the active components in the system.

---

Key Research Limitations and Uncertainties

Research provides context but not individual predictions, and research is ongoing regarding the patterns observed during prolonged use. There is limited information for long-term outcomes because follow-up durations were constrained in most controlled studies. Specifically, data characterizing patterns of use beyond four weeks are not fully established. Additionally, the evidence base includes older studies, and comparative evidence is lacking. Study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly. Findings describe group patterns, not personal outcomes.

Key Studies & References

1. Label: FLURAZEPAM HYDROCHLORIDE capsule - DailyMed
2. Meta-analysis of benzodiazepine use in the treatment of insomnia - CMAJ
3. Toxicity of High-Dose Flurazepam in the Elderly - PubMed
4. Long-term use of benzodiazepines in chronic insomnia: a European perspective - Frontiers

Common questions about Dalmane (FAQ)

---

Q: What happens if I miss a dose of flurazepam?

Official regulatory documents indicate that the medication is intended to be taken only at bedtime when a full night of sleep is possible. If a dose is forgotten, the product information advises against taking a double dose to compensate. The medication should be resumed at the next scheduled bedtime.

---

Q: Can I drink coffee or caffeine while taking this drug?

The official product label explicitly prohibits the use of alcohol due to severe central nervous system (CNS) effects. While caffeine is not specifically named as an interaction, since the drug is intended to facilitate sleep, the use of stimulants like coffee or caffeine may interfere with its desired effect.

---

Q: How quickly can I expect flurazepam to start working after I take it?

Studies and official information indicate that flurazepam is rapidly absorbed after ingestion, and peak concentration in the blood is typically reached within 30 to 60 minutes after taking the capsule. Due to the drug's profile, the maximum effect on sleep may be more evident during the second or third night of consecutive use.

---

Q: Is flurazepam approved for long-term use?

The drug is indicated by regulatory authorities for the short-term management of insomnia. Official product information states that the clinical safety and efficacy data for use beyond four consecutive weeks are limited. Therefore, use beyond this duration is usually discouraged and requires a re-evaluation of the patient's condition.

---

Q: Are there any dietary restrictions or specific foods I should avoid while taking flurazepam?

Official information does not specify any general dietary restrictions or foods to avoid, and patients are advised to maintain their normal diet unless their healthcare provider gives specific instructions. The most critical restriction is the explicit prohibition of consuming alcohol, which can significantly increase the risk of severe CNS depression.

---

Q: What should I do if my insomnia does not improve after a few weeks?

Official product information advises that the failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary medical or psychiatric illness. If sleep problems do not improve or if they worsen, it is necessary to consult with a healthcare professional for re-evaluation of the underlying cause.

---

Q: What are the symptoms of a flurazepam overdose?

Symptoms of overdose are mainly an extension of the known effects of the drug, which may include extreme drowsiness, confusion, and coma. A key risk noted in the official safety information is the potential for severe central nervous system and respiratory depression, especially when combined with alcohol or other depressants.

---

Q: What is the difference between the 15 mg and 30 mg capsules?

The drug is supplied in both strengths. Official product information suggests the 15 mg dose may be sufficient for many individuals and can help minimize residual effects on awakening. The 30 mg dose may be appropriate for more severe insomnia, though it is noted that this strength may be associated with a higher frequency of residual effects like daytime sedation.

Storage and Disposal of Dalmane (Flurazepam Hydrochloride)

Requirement	Official Regulatory Statement
Storage Temperature	Store at 20^circ to 25 C (68^circ to 77 F), per USP Controlled Room Temperature.
Protection	Protect from light and moisture. Store in a dry place away from excessive heat.
Child Safety	KEEP THIS MEDICINE OUT OF THE REACH OF CHILDREN AND PETS.
Disposal	Unused or expired medication must be disposed of following specific instructions, preferably by using a drug take-back program. As a controlled substance, it must be rendered non-retrievable; do not flush unless specifically authorized.

Official labeling defines storage constraints by mandating Controlled Room Temperature and requiring that the capsules be shielded from light and excess moisture to ensure product quality. Due to the medication's nature as a Schedule IV controlled substance, child-protection storage is a mandatory requirement. Disposal must comply with federal guidelines, prioritizing take-back programs to minimize misuse and environmental risks.